了解膀胱癌的分子发病机制和预后：综述。
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview.
作者信息
Zhao Ming, He Xiang-Lei, Teng Xiao-Dong
机构信息
1 Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China ; 2 Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
出版信息
Chin J Cancer Res. 2016 Feb;28(1):92-8. doi: 10.3978/j.issn.1000-9604.2016.02.05.
Abstract
The knowledge of cellular mechanisms in malignances of the bladder has grown exponentially. Molecular technologies have led to the discovery of the molecular pathways distinguishing low-and high-grade urothelial neoplasms. This trend portends the future in which the classification and diagnosis of the bladder tumors through morphologic analysis will be supported by molecular information correlating with prognosis and targeted therapy. This article outlines tumor molecular pathology of bladder cancer with an emphasis on several promising candidate biomarkers that may soon make their transition to the realm of clinical management of bladder cancer.
摘要
膀胱恶性肿瘤细胞机制的知识呈指数级增长。分子技术已促使人们发现区分低级别和高级别尿路上皮肿瘤的分子途径。这一趋势预示着未来通过形态学分析对膀胱肿瘤进行分类和诊断将得到与预后及靶向治疗相关的分子信息的支持。本文概述了膀胱癌的肿瘤分子病理学，重点介绍了几种有望很快过渡到膀胱癌临床管理领域的候选生物标志物。
相似文献
1
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview.
Chin J Cancer Res. 2016 Feb;28(1):92-8. doi: 10.3978/j.issn.1000-9604.2016.02.05.
2
Molecular Pathology of the Genitourinary Tract: Prostate and Bladder.
Surg Pathol Clin. 2008 Dec;1(1):211-36. doi: 10.1016/j.path.2008.08.002. Epub 2008 Dec 6.
3
Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes.
Surg Pathol Clin. 2009 Mar;2(1):199-223. doi: 10.1016/j.path.2008.08.003. Epub 2009 Jan 27.
4
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
J Pers Med. 2023 Apr 28;13(5):756. doi: 10.3390/jpm13050756.
5
Molecular Pathology of Bladder Cancer.
Surg Pathol Clin. 2012 Dec;5(4):843-58. doi: 10.1016/j.path.2012.08.003. Epub 2012 Sep 28.
6
An update on the molecular pathology of urinary bladder tumors.
Pathol Res Pract. 2018 Jan;214(1):1-6. doi: 10.1016/j.prp.2017.11.003. Epub 2017 Nov 10.
7
H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
J Pediatr Urol. 2016 Apr;12(2):91.e1-7. doi: 10.1016/j.jpurol.2015.08.020. Epub 2015 Oct 22.
8
Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
Adv Anat Pathol. 2011 Jan;18(1):79-89. doi: 10.1097/PAP.0b013e318204c0cf.
9
Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems.
J Urol. 2007 Oct;178(4 Pt 1):1196-200; discussion 1200. doi: 10.1016/j.juro.2007.05.126. Epub 2007 Aug 14.
10
Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.
Endocr Pathol. 2016 Sep;27(3):188-99. doi: 10.1007/s12022-016-9444-5.
引用本文的文献
1
DGKα Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease.
Cancer Med. 2025 Mar;14(5):e70710. doi: 10.1002/cam4.70710.
2
Predicting survival in bladder cancer with a novel apoptotic gene-related prognostic model.
Discov Oncol. 2024 Nov 24;15(1):702. doi: 10.1007/s12672-024-01575-z.
3
The diagnostic accuracy of urine-derived exosomes for bladder cancer: a systematic review and meta-analysis.
World J Surg Oncol. 2024 Oct 29;22(1):285. doi: 10.1186/s12957-024-03569-1.
4
Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
BMC Cancer. 2024 Aug 8;24(1):971. doi: 10.1186/s12885-024-12683-y.
5
Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
Ther Adv Med Oncol. 2024 May 10;16:17588359241249068. doi: 10.1177/17588359241249068. eCollection 2024.
6
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
Sci Rep. 2023 Sep 8;13(1):14803. doi: 10.1038/s41598-023-41992-8.
7
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
J Pers Med. 2023 Apr 28;13(5):756. doi: 10.3390/jpm13050756.
8
The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.
Biomedicines. 2023 Feb 13;11(2):539. doi: 10.3390/biomedicines11020539.
9
A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.
Front Oncol. 2021 Aug 6;11:686044. doi: 10.3389/fonc.2021.686044. eCollection 2021.
10
Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
Mol Biol Rep. 2021 May;48(5):4361-4371. doi: 10.1007/s11033-021-06451-5. Epub 2021 Jun 4.
本文引用的文献
1
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.
Nat Rev Cancer. 2015 Jan;15(1):25-41. doi: 10.1038/nrc3817.
2
Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer.
J Natl Cancer Inst. 2014 Oct 24;106(11). doi: 10.1093/jnci/dju290. Print 2014 Nov.
3
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Clin Genitourin Cancer. 2015 Feb;13(1):e37-49. doi: 10.1016/j.clgc.2014.07.010. Epub 2014 Aug 1.
4
Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder.
Pathology. 2014 Jun;46(4):274-82. doi: 10.1097/PAT.0000000000000110.
5
Comprehensive molecular characterization of urothelial bladder carcinoma.
Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.
6
Clinical performance and utility of a DNA methylation urine test for bladder cancer.
Urol Oncol. 2014 Jan;32(1):51.e21-6. doi: 10.1016/j.urolonc.2013.08.003.
7
Urine markers for detection and surveillance of bladder cancer.
Urol Oncol. 2014 Apr;32(3):222-9. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17.
8
Biomarkers in bladder cancer: translational and clinical implications.
Crit Rev Oncol Hematol. 2014 Jan;89(1):73-111. doi: 10.1016/j.critrevonc.2013.08.008. Epub 2013 Aug 29.
9
Copy number aberrations using multicolour fluorescence in situ hybridization (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).
BJU Int. 2014 Apr;113(4):662-7. doi: 10.1111/bju.12232. Epub 2013 Jul 26.
10
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.
Cancer. 2013 Feb 15;119(4):756-65. doi: 10.1002/cncr.27763. Epub 2013 Jan 14.
Zotero 插件